Lakefront Biotherapeutics NVGLPGF 57 Net Current Asset Value is $51.61 as of Mar. 2026, which is 3066% above its 10-year median of 1.63. GuruFocus rates GLPGF with a GF Score™ of 57/100 and a GF Value™ of $113.44. The stock has 4 warning signs investors should review. Among 942 Biotechnology companies, Lakefront Biotherapeutics NV ranks better than 96.5% on this metric.
In calculating the Net Current Asset Value (NCAV), Benjamin Graham means a company's current assets (such as cash, marketable securities, and inventories) minus its total liabilities (including preferred stock, minority interest, and long-term debt).
Lakefront Biotherapeutics NV's net current asset value per share for the quarter that ended in Mar. 2026 was $51.61.
The historical rank and industry rank for Lakefront Biotherapeutics NV's Net Current Asset Value or its related term are showing as below:
GLPGF'
s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 0.59 Med: 1.63 Max: 6.26
Current: 0.6
During the past 13 years, the highest Price-to-Net-Current-Asset-Value Ratio of Lakefront Biotherapeutics NV was 6.26. The lowest was 0.59. And the median was 1.63.
GLPGF's Price-to-Net-Current-Asset-Value is ranked better than 96.5% of 942
companies
in the Biotechnology industry
Industry Median: 4.875
vs GLPGF: 0.60
Lakefront Biotherapeutics NV (OTCPK:GLPGF) Net Current Asset Value Explanation
Benjamin Graham first discussed net current asset value (NCAV) in the 1934 edition of "Security Analysis", which he coauthored with David Dodd. In the book, (net) current asset value is defined as:" current assets alone, minus all liabilities and claims ahead of the issue."
The common definition of NCAV is: NCAV = current assets – [total liabilities + minority interest + preferred stock]
Net current assets exclude not only the intangible assets but also the fixed and miscellaneous assets. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.
One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Grahams strategy produced similar results.
Benjamin Graham looked for companies whose market values were less than two-thirds of their Net-Net Working Capital. They are collected under our Net-Net screener.
Lakefront Biotherapeutics NV Net Current Asset Value Related Terms
Lakefront Biotherapeutics NV Net Current Asset Value Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lakefront Biotherapeutics NV Net Current Asset Value Chart
GLPGF vs VRTX, REGN, ALNY: Net Current Asset Value Comparison
For the Biotechnology subindustry, Lakefront Biotherapeutics NV's Price-to-Net-Current-Asset-Value, along with its competitors' market caps and Price-to-Net-Current-Asset-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lakefront Biotherapeutics NV Price-to-Net-Current-Asset-Value vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Lakefront Biotherapeutics NV's Price-to-Net-Current-Asset-Value distribution charts can be found below:
* The bar in red indicates where Lakefront Biotherapeutics NV's Price-to-Net-Current-Asset-Value falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Net Current Asset Value of $51.61 mean?
Lakefront Biotherapeutics NV (GLPGF) has a Net Current Asset Value of $51.61 as of Mar. 2026. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on Lakefront Biotherapeutics NV and its competitors. This is 3066% above median its historical median of 1.63. Over the past decade, Lakefront Biotherapeutics NV's Net Current Asset Value has ranged from 0.59 to 6.26. According to the industry distribution chart, Lakefront Biotherapeutics NV ranks #33 out of 942 companies in the Biotechnology industry, placing it in the top 3.5%.
Is Lakefront Biotherapeutics NV's Net Current Asset Value too high?
Lakefront Biotherapeutics NV's current Net Current Asset Value of $51.61 is 3066% above median its 10-year median of 1.63. Over the past 10 years, this metric has ranged from a low of 0.59 to a high of 6.26. The Biotechnology industry median Net Current Asset Value is 4.88. Lakefront Biotherapeutics NV's value of $51.61 is 958.7% above this industry median. Based on the distribution chart, Lakefront Biotherapeutics NV ranks #33 out of 942 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Lakefront Biotherapeutics NV has a GF Score™ of 57/100, reflecting its overall financial health beyond just this single metric.
How does Lakefront Biotherapeutics NV's Net Current Asset Value compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Lakefront Biotherapeutics NV ranks #33 out of 942 companies for Net Current Asset Value. This places Lakefront Biotherapeutics NV in the top 4% of its industry — outperforming the majority of peers. The industry median Net Current Asset Value is 4.88. Lakefront Biotherapeutics NV's value of $51.61 is 958.7% above this benchmark. Historically, Lakefront Biotherapeutics NV's own Net Current Asset Value has ranged from 0.59 to 6.26 over the past decade. While the company's 10-year median is 1.63 vs. the industry median of 4.88, Lakefront Biotherapeutics NV has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Current Asset Value for a Biotechnology company?
The median Net Current Asset Value among Biotechnology companies is 4.88, based on 942 companies in the industry. Companies in the top quartile (top 25%) have a Net Current Asset Value significantly above this median, while those in the bottom quartile fall well below. However, Net Current Asset Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Lakefront Biotherapeutics NV's current Net Current Asset Value of $51.61 is 958.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Current Asset Value mean?
A high Net Current Asset Value can signal that a stock is expensive relative to its fundamentals. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on Lakefront Biotherapeutics NV and its competitors. For the Biotechnology industry, the median Net Current Asset Value is 4.88 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Lakefront Biotherapeutics NV's current Net Current Asset Value is $51.61, which is 3066% above median its own 10-year median of 1.63. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lakefront Biotherapeutics NV stock overvalued right now?
Lakefront Biotherapeutics NV (GLPGF) has a current Net Current Asset Value of $51.61. The stock's GF Value™ is $113.44, compared to a current price of $28.08 — trading 75.2% below its estimated fair value. The current Net Current Asset Value is $51.61, which is 3066% above median its 10-year median of 1.63 and 958.7% above the Biotechnology industry median of 4.88. Lakefront Biotherapeutics NV's overall GF Score™ is 57/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Current Asset Value calculated?
Net Current Asset Value is calculated from a company's financial statements. For Lakefront Biotherapeutics NV (GLPGF), the current Net Current Asset Value is $51.61 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Lakefront Biotherapeutics NV (GLPGF) Overvalued in 2026?
Based on GuruFocus' analysis, Lakefront Biotherapeutics NV stock appears to be undervalued.
The current stock price of $28.08 is trading 75.2% below its estimated GF Value™ of $113.44.
Key valuation signals for GLPGF:
Net Current Asset Value: $51.61 (3066% above median its 10-year median of 1.63)
GF Value™: $113.44 vs. price of $28.08 (75.2% below fair value)
Industry Position: 958.7% above the Biotechnology median (#33 of 942)
No single metric tells the full story. See the GLPGF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Lakefront Biotherapeutics NV a biopharmaceutical company committed to improving the lives of people with severe diseases. It focuses on delivering medicines with transformational impact for patients by accelerating life-changing science and innovation in areas of high unmet need. Its pipelines includes GLPG3667, GLPG5101, and GLPG5301.
57GF Score
Get the complete analysis for GLPGF
Net Current Asset Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
GLPGF has been successfully added to your 
